This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.
Elsewhere in this issue a group of investigators have presented a summary of their studies on attenuated measles vaccine together with their evaluation of the present status of this exciting development in immunization. This short paper, one of eight appearing in a recent issue of The New England Journal of Medicine devoted in its entirety to studies on attenuated measles vaccine, represents the cooperative studies of a number of investigators who have in a unique way combined their efforts to provide a carefully planned evaluation of a live attenuated measles virus vaccine first developed by Dr. John F. Enders and his associates between 1954 and 1958.
In short, this live modified virus vaccine, requiring a single subcutaneous injection of 0.2 ml., results in a 2- to-3-day febrile illness from 7 to 8 days after inoculation. The mean maximum fever is 102.4 F by rectum, but there is apparent well-being in
KEMPE CH. Attenuated Measles Vaccine (Enders)—The Next Big Advance?. Am J Dis Child. 1960;100(6):807-808. doi:10.1001/archpedi.1960.04020040809001